

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam.

After reconstitution, 1 mL of solution contains 167.3 mg of ceftazidime and 41.8 mg of avibactam (see section 6.6).

### Excipient with known effect:

Zavicefta contains approximately 146 mg sodium per vial.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Powder for concentrate for solution for infusion (powder for concentrate).

A white to yellow powder.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Zavicefta is indicated in adults and paediatric patients from birth for the treatment of the following infections (see sections 4.4 and 5.1):

- Complicated intra-abdominal infection (cIAI)
- Complicated urinary tract infection (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)

Treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients from birth with limited treatment options (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

### **4.2 Posology and method of administration**

It is recommended that Zavicefta should be used to treat infections due to aerobic Gram-negative organisms in adults and paediatric patients from birth with limited treatment options only after consultation with a physician with appropriate experience in the management of infectious diseases (see section 4.4).

## Posology

### *Dosage in adults with creatinine clearance (CrCL) > 50 mL/min*

Table 1 shows the recommended intravenous dose for adults with estimated creatinine clearance (CrCL) > 50 mL/min (see sections 4.4 and 5.1).

Table 1: Recommended dose for adults with estimated CrCL > 50 mL/min<sup>1</sup>

Type of infection	Dose of ceftazidime/avibactam	Frequency	Infusion time	Duration of treatment
cIAI <sup>2,3</sup>	2 g/0.5 g	Every 8 hours	2 hours	5-14 days
cUTI, including pyelonephritis <sup>3</sup>	2 g/0.5 g	Every 8 hours	2 hours	5-10 days <sup>4</sup>
HAP/VAP <sup>3</sup>	2 g/0.5 g	Every 8 hours	2 hours	7-14 days
Bacteraemia associated with, or suspected to be associated with any of the above infections	2 g/0.5 g	Every 8 hours	2 hours	Duration of treatment should be in accordance with the site of infection.
Infections due to aerobic Gram-negative organisms in patients with limited treatment options <sup>2,3</sup>	2 g/0.5 g	Every 8 hours	2 hours	Guided by the severity of the infection, the pathogen(s) and the patient's clinical and bacteriological progress <sup>5</sup>

<sup>1</sup> CrCL estimated using the Cockcroft-Gault formula.

<sup>2</sup> To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

<sup>3</sup> To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.

<sup>4</sup> The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.

<sup>5</sup> There is very limited experience with the use of Zavicefta for more than 14 days.

### *Dosage in paediatric patients with creatinine clearance (CrCL) > 50 mL/min/1.73 m<sup>2</sup>*

Table 2 shows the recommended intravenous doses for paediatric patients with estimated creatinine clearance (CrCL) > 50 mL/min/1.73 m<sup>2</sup> (see sections 4.4 and 5.1).

Table 2: Recommended dose for paediatric patients from 3 months of age with estimated CrCL<sup>1</sup> > 50 mL/min/1.73 m<sup>2</sup>

Type of infection	Age group <sup>8</sup>	Dose of ceftazidime/avibactam <sup>7</sup>	Frequency	Infusion time	Duration of treatment
cIAI <sup>2,3</sup> OR cUTI including pyelonephritis <sup>3</sup> OR HAP/VAP <sup>3</sup> OR Infections due to aerobic Gram-negative organisms in patients with limited treatment options (LTO) <sup>2,3</sup>	6 months to < 18 years	<b>50 mg/kg/12.5 mg/kg</b>  <b>to a maximum of</b>  <b>2 g/0.5 g</b>	Every 8 hours	2 hours	cIAI: 5 – 14 days  cUTI <sup>4</sup> : 5 – 14 days
			Every 8 hours	2 hours	HAP/VAP: 7 – 14 days  LTO: Guided by the severity of the infection, the pathogen(s) and the patient's clinical and bacteriological progress <sup>5</sup>
	3 months to < 6 months <sup>6</sup>	<b>40 mg/kg/10 mg/kg</b>	Every 8 hours	2 hours	

<sup>1</sup> CrCL estimated using the Schwartz bedside formula.

<sup>2</sup> To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

<sup>3</sup> To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.

<sup>4</sup> The total treatment duration shown may include intravenous Zavicefta followed by appropriate oral therapy.

<sup>5</sup> There is very limited experience with the use of Zavicefta for more than 14 days.

<sup>6</sup> There is limited experience with the use of Zavicefta in paediatric patients 3 months to < 6 months (see section 5.2).

<sup>7</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).

<sup>8</sup> Paediatric patients studied from 3 to 12 months of age were full term (≥37 weeks gestation).

Table 3: Recommended dose for paediatric patients less than 3 months of age<sup>9</sup>

Type of infection	Age group		Dose of ceftazidime/avibactam <sup>5</sup>	Frequency	Infusion time	Duration of treatment
cIAI <sup>1,2</sup> OR cUTI including pyelonephritis <sup>2</sup> OR	Full term neonates and infants	> 28 days to < 3 months	<b>30 mg/kg/7.5 mg/kg</b>	Every 8 hours	2 hours	cIAI: 5 – 14 days  cUTI <sup>3</sup> : 5 – 14 days  HAP/VAP: 7 – 14 days
		Birth to ≤ 28 days	<b>20 mg/kg/5 mg/kg</b>			
HAP/VAP <sup>2</sup> OR Infections due to aerobic Gram-negative organisms in patients with limited treatment options (LTO) <sup>1,2</sup>	Preterm neonates and infants <sup>6</sup>	> 44 weeks to < 53 weeks PMA <sup>7</sup>	<b>30 mg/kg/7.5 mg/kg</b>	Every 8 hours	2 hours	LTO: Guided by the severity of the infection, the pathogen(s) and the patient's clinical and bacteriological progress <sup>4</sup>
		31 to ≤ 44 weeks PMA <sup>7</sup>	<b>20 mg/kg/5 mg/kg</b>			
		26 to < 31 weeks PMA <sup>7,8</sup>	<b>20 mg/kg/5 mg/kg</b>	Every 12 hours	2 hours	

<sup>1</sup> To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

<sup>2</sup> To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.

<sup>3</sup> The total treatment duration shown may include intravenous Zavicefta followed by appropriate oral therapy.

<sup>4</sup> There is very limited experience with the use of Zavicefta for more than 14 days.

<sup>5</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).

<sup>6</sup> Preterm defined as < 37 weeks gestation.

<sup>7</sup> Postmenstrual age.

<sup>8</sup> Dose recommendations for patients 26 to < 31 weeks PMA are based on pharmacokinetic modelling only (see section 5.2).

<sup>9</sup> Patients with serum creatinine at or below the upper limit of normal for age.

### Special populations

#### *Elderly*

No dosage adjustment is required in elderly patients (see section 5.2).

#### *Renal impairment*

Table 4 shows the recommended dose adjustments for adults with estimated CrCL ≤ 50 mL/min (see sections 4.4 and 5.2).

*Dosage in adults with CrCL ≤ 50 mL/min*

Table 4: Recommended dose for adults with estimated CrCL<sup>1</sup> ≤ 50 mL/min

Age group	Estimated CrCL (mL/min)	Dose of ceftazidime/avibactam <sup>2,4</sup>	Frequency	Infusion time
Adults	31-50	<b>1 g/0.25 g</b>	Every 8 hours	2 hours
	16-30	<b>0.75 g/0.1875 g</b>	Every 12 hours	
	6-15		Every 24 hours	
	End Stage Renal Disease including on haemodialysis <sup>3</sup>		Every 48 hours	

<sup>1</sup> CrCL estimated using the Cockcroft-Gault formula.

<sup>2</sup> Dose recommendations are based on pharmacokinetic modelling (see section 5.2).

<sup>3</sup> Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2). Dosing of Zavicefta on haemodialysis days should occur after completion of haemodialysis.

<sup>4</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).

Table 5 and Table 6 show the recommended dose adjustments for paediatric patients with estimated CrCL ≤ 50 mL/min/1.73 m<sup>2</sup> according to different age groups (see sections 4.4 and 5.2).

*Dosage in paediatric patients ≥ 2 years of age with CrCl ≤ 50 mL/min/1.73 m<sup>2</sup>*

Table 5: Recommended dose for paediatric patients aged 2 years to < 18 years with estimated CrCL<sup>1</sup> ≤ 50 mL/min/1.73 m<sup>2</sup>

Age group	Estimated CrCL (mL/min/1.73 m <sup>2</sup> )	Dose of ceftazidime/avibactam <sup>2,4</sup>	Frequency	Infusion time
Paediatric patients aged 2 years to < 18 years	31-50	<b>25 mg/kg/6.25 mg/kg to a maximum of 1 g/0.25 g</b>	Every 8 hours	2 hours
	16-30	<b>18.75 mg/kg/4.7 mg/kg to a maximum of 0.75 g/0.1875 g</b>	Every 12 hours	
	6-15		Every 24 hours	
	End Stage Renal Disease including on haemodialysis <sup>3</sup>		Every 48 hours	

<sup>1</sup> CrCL estimated using the Schwartz bedside formula.

<sup>2</sup> Dose recommendations are based on pharmacokinetic modelling (see section 5.2).

<sup>3</sup> Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2). Dosing of Zavicefta on haemodialysis days should occur after completion of haemodialysis.

<sup>4</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).

*Dosage in paediatric patients 3 months to < 2 years of age with CrCl ≤ 50 mL/min/1.73 m<sup>2</sup>*

Table 6: Recommended dose for paediatric patients aged 3 months to < 2 years with estimated CrCL<sup>1</sup> ≤ 50 mL/min/1.73 m<sup>2</sup>

Age group <sup>4</sup>	Estimated CrCL (mL/min/1.73 m <sup>2</sup> )	Dose of ceftazidime/avibactam <sup>2,3</sup>	Frequency	Infusion time
6 months to < 2 years	31 to 50	<b>25 mg/kg/6.25 mg/kg</b>	Every 8 hours	2 hours
3 to < 6 months		<b>20 mg/kg/5 mg/kg</b>	Every 8 hours	
6 months to < 2 years	16 to 30	<b>18.75 mg/kg/4.7 mg/kg</b>	Every 12 hours	
3 to < 6 months		<b>15 mg/kg/3.75 mg/kg</b>	Every 12 hours	

<sup>1</sup> Calculated using the Schwartz bedside formula.

<sup>2</sup> Dose recommendations are based on pharmacokinetic modelling (see section 5.2).

<sup>3</sup> Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only (see section 6.6).

<sup>4</sup> Paediatric patients studied from 3 to 12 months of age were full term (≥ 37 weeks gestation).

There is insufficient information to recommend a dosage regimen for paediatric patients aged 3 months to < 2 years of age that have a CrCL < 16 mL/min/1.73 m<sup>2</sup>.

There is insufficient information to recommend a dosage regimen for paediatric patients from birth to 3 months of age with signs of renal impairment.

#### *Hepatic impairment*

No dosage adjustment is required in patients with hepatic impairment (see section 5.2).

#### Method of administration

Intravenous use.

Zavicefta is administered by intravenous infusion over 120 minutes in an appropriate infusion volume (see section 6.6).

For instructions on reconstitution and dilution of the medicinal product before administration see section 6.6.

### **4.3 Contraindications**

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Hypersensitivity to any cephalosporin antibacterial agent.

Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of β-lactam antibacterial agent (e.g. penicillins, monobactams or carbapenems).

## 4.4 Special warnings and precautions for use

### Hypersensitivity reactions

Serious and occasionally fatal hypersensitivity reactions are possible (see sections 4.3 and 4.8). In case of hypersensitivity reactions, treatment with Zavicefta must be discontinued immediately and adequate emergency measures must be initiated.

There have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8).

Before beginning treatment, it should be established whether the patient has a history of hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of  $\beta$ -lactam antibacterial agent. Caution should be used if ceftazidime/avibactam is given to patients with a history of non-severe hypersensitivity to penicillins, monobactams or carbapenems.

Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported with unknown frequency in association with ceftazidime treatment (see section 4.8).

Patients should be advised of the signs and symptoms and monitored closely for skin reactions.

If signs and symptoms suggestive of these reactions appear, Zavicefta should be withdrawn immediately, and an alternative treatment considered.

If the patient has developed a serious reaction such as SJS, TEN, DRESS or AGEP with the use of ceftazidime, treatment with Zavicefta must not be restarted in this patient at any time.

### *Clostridioides difficile* - associated diarrhoea

*Clostridioides difficile* - associated diarrhoea has been reported with ceftazidime/avibactam, and can range in severity from mild to life-threatening. This diagnosis should be considered in patients who present with diarrhoea during or subsequent to the administration of Zavicefta (see section 4.8). Discontinuation of therapy with Zavicefta and the administration of specific treatment for *Clostridioides difficile* should be considered. Medicinal products that inhibit peristalsis should not be given.

### Renal impairment

Ceftazidime and avibactam are eliminated via the kidneys, therefore, the dose should be reduced according to the degree of renal impairment (see section 4.2). Neurological sequelae, including tremor, myoclonus, non-convulsive status epilepticus, convulsion, encephalopathy and coma, have occasionally been reported with ceftazidime when the dose has not been reduced in patients with renal impairment.

In patients with renal impairment, close monitoring of estimated creatinine clearance is advised. In some patients, the creatinine clearance estimated from serum creatinine can change quickly, especially early in the course of treatment for the infection.

### Nephrotoxicity

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.



### Direct antiglobulin test (DAGT or Coombs test) seroconversion and potential risk of haemolytic anaemia

Ceftazidime/avibactam use may cause development of a positive direct antiglobulin test (DAGT, or Coombs test), which may interfere with the cross-matching of blood and/or may cause drug induced immune haemolytic anaemia (see section 4.8). While DAGT seroconversion in patients receiving Zavicefta was very common in clinical studies (the estimated range of seroconversion across Phase 3 studies was 3.2% to 20.8% in patients with a negative Coombs test at baseline and at least one follow-up test), there was no evidence of haemolysis in patients who developed a positive DAGT on treatment. However, the possibility that haemolytic anaemia could occur in association with Zavicefta treatment cannot be ruled out. Patients experiencing anaemia during or after treatment with Zavicefta should be investigated for this possibility.

### Limitations of the clinical data

Clinical efficacy and safety studies of Zavicefta have been conducted in cIAI, cUTI and HAP (including VAP).

#### *Complicated intra-abdominal infections in adults*

In two studies in patients with cIAI, the most common diagnosis (approximately 42%) was appendiceal perforation or peri-appendiceal abscess. Approximately 87% of patients had APACHE II scores of  $\leq 10$  and 4% had bacteraemia at baseline. Death occurred in 2.1% (18/857) of patients who received Zavicefta and metronidazole and in 1.4% (12/863) of patients who received meropenem.

Among a subgroup with baseline CrCL 30 to 50 mL/min death occurred in 16.7% (9/54) of patients who received Zavicefta and metronidazole and 6.8% (4/59) of patients who received meropenem. Patients with CrCL 30 to 50 mL/min received a lower dose of Zavicefta than is currently recommended for patients in this sub-group.

#### *Complicated urinary tract infections in adults*

In two studies in patients with cUTI, 381/1091 (34.9%) patients were enrolled with cUTI without pyelonephritis while 710 (65.1%) were enrolled with acute pyelonephritis (mMITT population). A total of 81 cUTI patients (7.4%) had bacteraemia at baseline.

#### *Hospital-acquired pneumonia (including ventilator-associated pneumonia) in adults*

In a single study in patients with nosocomial pneumonia 280/808 (34.7%) had VAP and 40/808 (5%) were bacteraemic at baseline.

#### *Patients with limited treatment options*

The use of ceftazidime/avibactam to treat patients with infections due to Gram-negative aerobic pathogens who have limited treatment options is based on experience with ceftazidime alone and on analyses of the pharmacokinetic-pharmacodynamic relationship for ceftazidime/avibactam (see section 5.1).

### Spectrum of activity of ceftazidime/avibactam

Ceftazidime has little or no activity against the majority of Gram-positive organisms and anaerobes (see sections 4.2 and 5.1). Additional antibacterial agents should be used when these pathogens are known or suspected to be contributing to the infectious process.

The inhibitory spectrum of avibactam includes many of the enzymes that inactivate ceftazidime, including Ambler class A  $\beta$ -lactamases and class C  $\beta$ -lactamases. Avibactam does not inhibit class B enzymes (metallo- $\beta$ -lactamases) and is not able to inhibit many of the class D enzymes (see section 5.1).

### Non-susceptible organisms

Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. enterococci, fungi), which may require interruption of treatment or other appropriate measures.

### Interference with laboratory tests

Ceftazidime may interfere with copper reduction methods (Benedict's, Fehling's, Clinitest) for detection of glycosuria leading to false positive results. Ceftazidime does not interfere with enzyme-based tests for glycosuria.

### Controlled sodium diet

This medicinal product contains approximately 146 mg sodium per vial, equivalent to 7.3% of the WHO recommended maximum daily intake (RDI) of 2 g sodium for an adult.

The maximum daily dose of this product is equivalent to 22% of the WHO recommended maximum daily intake for sodium. Zavicefta is considered high in sodium. This should be considered when administering Zavicefta to patients who are on a controlled sodium diet.

Zavicefta may be diluted with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.

### Paediatric population

There is a potential risk of overdosing, particularly for paediatric patients from birth to less than 12 months of age. Care should be taken when calculating the volume of administration of the dose (see sections 4.9 and 6.6).

## **4.5 Interaction with other medicinal products and other forms of interaction**

*In vitro*, avibactam is a substrate of OAT1 and OAT3 transporters which might contribute to the active uptake of avibactam from the blood compartment and, therefore, affect its excretion. Probenecid (a potent OAT inhibitor) inhibits this uptake by 56% to 70% *in vitro* and, therefore, has the potential to alter the elimination of avibactam. Since a clinical interaction study of avibactam and probenecid has not been conducted, co-administration of avibactam with probenecid is not recommended.

Avibactam showed no significant inhibition of cytochrome P450 enzymes *in vitro*. Avibactam and ceftazidime showed no *in vitro* cytochrome P450 induction at clinically relevant concentrations. Avibactam and ceftazidime do not inhibit the major renal or hepatic transporters in the clinically relevant exposure range, therefore the interaction potential via these mechanisms is considered to be low.

Clinical data have demonstrated that there is no interaction between ceftazidime and avibactam, and between ceftazidime/avibactam and metronidazole.

#### *Other types of interaction*

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function (see section 4.4).

Chloramphenicol is antagonistic *in vitro* with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but due to the possibility of antagonism *in vivo* this drug combination should be avoided.

## **4.6 Fertility, pregnancy and lactation**

### Pregnancy

Animal studies with ceftazidime do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Animal studies with avibactam have shown reproductive toxicity without evidence of teratogenic effects (see section 5.3).

Ceftazidime/avibactam should only be used during pregnancy if the potential benefit outweighs the possible risk.

### Breast-feeding

Ceftazidime is excreted in human milk in small quantities. It is unknown whether avibactam is excreted in human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast feeding or to discontinue/abstain from ceftazidime/avibactam therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

### Fertility

The effects of ceftazidime/avibactam on fertility in humans have not been studied. No data are available on animal studies with ceftazidime. Animal studies with avibactam do not indicate harmful effects with respect to fertility (see section 5.3).

## **4.7 Effects on ability to drive and use machines**

Undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines following administration of Zavicefta (see section 4.8).

## **4.8 Undesirable effects**

### Summary of the safety profile

In seven Phase 2 and Phase 3 clinical trials, 2024 adults were treated with Zavicefta. The most common adverse reactions occurring in  $\geq 5\%$  of patients treated with Zavicefta were Coombs direct test positive, nausea, and diarrhoea. Nausea and diarrhoea were usually mild or moderate in intensity.

### Tabulated list of adverse reactions

The following adverse reactions have been reported with ceftazidime alone and/or identified during the Phase 2 and Phase 3 trials with Zavicefta. Adverse reactions are classified according to frequency and System Organ Class. Frequency categories are derived from adverse reactions and/or potentially clinically significant laboratory abnormalities, and are defined according to the following conventions:

Very common ( $\geq 1/10$ )

Common ( $\geq 1/100$  and  $< 1/10$ )

Uncommon ( $\geq 1/1,000$  and  $< 1/100$ )

Rare ( $\geq 1/10,000$  and  $< 1/1000$ )

Very rare ( $< 1/10,000$ )

Not known (cannot be estimated from the available data)

Table 7: Frequency of adverse reactions by system organ class

<b>System organ class</b>	<b>Very common</b>	<b>Common</b>	<b>Uncommon</b>	<b>Very rare</b>	<b>Not known</b>
Infections and infestations		Candidiasis (including Vulvovaginal candidiasis and Oral candidiasis)	Clostridioides difficile colitis  Pseudomembranous colitis		
Blood and lymphatic system disorders	Coombs direct test positive	Eosinophilia  Thrombocytosis  Thrombocytopenia	Neutropenia  Leukopenia  Lymphocytosis		Agranulocytosis  Haemolytic anaemia
Immune system disorders					Anaphylactic reaction
Nervous system disorders		Headache  Dizziness	Paraesthesia		
Cardiac disorders					Kounis syndrome <sup>a,*</sup>
Gastrointestinal disorders		Diarrhoea  Abdominal pain  Nausea  Vomiting	Dysgeusia		
Hepatobiliary disorders		Alanine aminotransferase increased  Aspartate aminotransferase increased  Blood alkaline phosphatase increased  Gamma-glutamyltransferase increased  Blood lactate dehydrogenase Increased			Jaundice
Skin and subcutaneous tissue disorders		Rash maculo-papular  Urticaria  Pruritus			Toxic epidermal necrolysis  Stevens-Johnson syndrome

System organ class	Very common	Common	Uncommon	Very rare	Not known
					Erythema multiforme  Angioedema  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)  Acute generalised exanthematous pustulosis (AGEP)*
Renal and urinary disorders			Blood creatinine increased  Blood urea increased  Acute kidney injury	Tubulointerstitial nephritis	
General disorders and administration site conditions		Infusion site thrombosis  Infusion site phlebitis  Pyrexia			

\* ADR identified post-marketing.

<sup>a</sup> Acute coronary syndrome associated with an allergic reaction.

### Paediatric population

#### *From birth to less than 3 months of age*

The safety assessment in neonates and infants less than 3 months of age is based on the safety data from one clinical trial in which 46 patients (from birth to less than 3 months of age) received Zavicefta. Overall, the adverse reactions reported in these 46 paediatric patients were consistent with the known safety profile of Zavicefta in older populations (i.e., paediatric patients from 3 months of age and adults).

#### *3 months of age and older*

The safety assessment in paediatric patients from 3 months of age and older is based on the safety data from two trials in which 61 patients (aged from 3 years to less than 18 years) with cIAI and 67 patients with cUTI (aged from 3 months to less than 18 years) received Zavicefta. Overall, the safety profile in these 128 paediatric patients was similar to that observed in the adult population with cIAI and cUTI.

## Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

### **4.9 Overdose**

Overdose with ceftazidime/avibactam can lead to neurological sequelae including encephalopathy, convulsions and coma, due to the ceftazidime component.

Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis. During a 4-hour haemodialysis period, 55% of the avibactam dose was removed.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antibacterials for systemic use, other beta-lactam antibacterials, third-generation cephalosporins, ATC code: J01DD52

#### Mechanism of action

Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death. Avibactam is a non  $\beta$ -lactam,  $\beta$ -lactamase inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis. It inhibits both Ambler class A and class C  $\beta$ -lactamases and some class D enzymes, including extended-spectrum  $\beta$ -lactamases (ESBLs), KPC and OXA-48 carbapenemases, and AmpC enzymes. Avibactam does not inhibit class B enzymes (metallo- $\beta$ -lactamases) and is not able to inhibit many class D enzymes.

#### Resistance

Bacterial resistance mechanisms that could potentially affect ceftazidime/avibactam include mutant or acquired PBPs, decreased outer membrane permeability to either compound, active efflux of either compound, and  $\beta$ -lactamase enzymes refractory to inhibition by avibactam and able to hydrolyse ceftazidime.

#### Antibacterial activity in combination with other antibacterial agents

No synergy or antagonism was demonstrated in *in vitro* drug combination studies with ceftazidime/avibactam and metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline.

#### Susceptibility testing breakpoints

Minimum Inhibitory Concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for ceftazidime/avibactam can be viewed on the following website:

[https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints\\_en.xlsx](https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx)

## Pharmacokinetic/pharmacodynamic relationship

The antimicrobial activity of ceftazidime against specific pathogens has been shown to best correlate with the percent time of free-drug concentration above the ceftazidime/avibactam minimum inhibitory concentration over the dose interval (%  $fT >MIC$  of ceftazidime/avibactam). For avibactam the PK-PD index is the percent time of the free drug concentration above a threshold concentration over the dose interval (%  $fT >C_T$ ).

## Clinical efficacy against specific pathogens

Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to ceftazidime/avibactam *in vitro*.

### **Complicated intra-abdominal infections**

Gram-negative micro-organisms

- *Citrobacter freundii*
- *Enterobacter cloacae*
- *Escherichia coli*
- *Klebsiella oxytoca*
- *Klebsiella pneumoniae*
- *Pseudomonas aeruginosa*

### **Complicated urinary-tract infections**

Gram-negative micro-organisms

- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Proteus mirabilis*
- *Enterobacter cloacae*
- *Pseudomonas aeruginosa*

### **Hospital-acquired pneumonia including ventilator-associated pneumonia**

Gram-negative micro-organisms

- *Enterobacter cloacae*
- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Proteus mirabilis*
- *Serratia marcescens*
- *Pseudomonas aeruginosa*

Clinical efficacy has not been established against the following pathogens that are relevant to the approved indications although *in vitro* studies suggest that they would be susceptible to ceftazidime/avibactam in the absence of acquired mechanisms of resistance.

Gram-negative micro-organisms

- *Citrobacter koseri*
- *Enterobacter aerogenes*
- *Morganella morganii*
- *Proteus vulgaris*
- *Providencia rettgeri*

*In vitro* data indicate that the following species are not susceptible to ceftazidime/avibactam.

- *Staphylococcus aureus* (methicillin-susceptible and methicillin-resistant)
- Anaerobes
- *Enterococcus* spp.

- *Stenotrophomonas maltophilia*
- *Acinetobacter* spp.

### Paediatric population

#### *From birth to less than 3 months of age*

Zavicefta has been evaluated in paediatric patients from birth to less than 3 months of age in a Phase 2a, 2-part (Part A and B), open-label, non-randomised clinical study in patients with suspected or confirmed infections due to Gram-negative pathogens. Part A used a single dose to assess the pharmacokinetic (PK) profile (primary objective) and evaluate safety and tolerability (secondary objective) of ceftazidime/avibactam. Part B used multiple doses to evaluate the safety and tolerability (primary objective) while the PK profile and efficacy were secondary objectives. Efficacy was only a descriptive endpoint. Clinical cure or clinical improvement rates in Part B were 81.0% (17/21) at TOC (ITT) and 75.0% (12/16) at TOC (modified-ITT). The microbiological eradication or presumed eradication rate at TOC (micro-ITT) was 80% (8/10).

#### *3 months of age and older*

Zavicefta has been evaluated in paediatric patients aged 3 months to < 18 years in two Phase 2 single-blind, randomised, comparative clinical studies, one in patients with cIAI and one in patients with cUTI. The primary objective in each study was to assess safety and tolerability of ceftazidime-avibactam (+/- metronidazole). Secondary objectives included assessment of pharmacokinetics and efficacy; efficacy was a descriptive endpoint in both studies. Clinical cure rate at TOC (ITT) was 91.8% (56/61) for Zavicefta compared to 95.5% (21/22) for meropenem in paediatric patients with cIAI. Microbiological eradication rate at TOC (micro-ITT) was 79.6% (43/54) for Zavicefta compared to 60.9% (14/23) for cefepime in paediatric patients with cUTI.

## **5.2 Pharmacokinetic properties**

### Distribution

The human protein binding of both ceftazidime and avibactam is approximately 10% and 8%, respectively. The steady-state volumes of distribution of ceftazidime and avibactam were about 17 L and 22 L, respectively in healthy adults following multiple doses of 2 g/0.5 g ceftazidime/avibactam infused over 2 hours every 8 hours. Both ceftazidime and avibactam penetrate into human bronchial epithelial lining fluid (ELF) to the same extent with concentrations around 30% of those in plasma. The concentration time profiles are similar for ELF and plasma.

Penetration of ceftazidime into the intact blood-brain barrier is poor. Ceftazidime concentrations of 4 to 20 mg/L or more are achieved in the CSF when the meninges are inflamed. Avibactam penetration of the blood brain barrier has not been studied clinically; however, in rabbits with inflamed meninges, CSF exposures of ceftazidime and avibactam were 43% and 38% of plasma AUC, respectively. Ceftazidime crosses the placenta readily, and is excreted in the breast milk.

### Biotransformation

Ceftazidime is not metabolised. No metabolism of avibactam was observed in human liver preparations (microsomes and hepatocytes). Unchanged avibactam was the major drug-related component in human plasma and urine following dosing with [<sup>14</sup>C]-avibactam.

### Elimination

The terminal half-life ( $t_{1/2}$ ) of both ceftazidime and avibactam is about 2 h after intravenous administration. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80-90% of the dose is recovered in the urine within 24 h. Avibactam is excreted unchanged into the urine with a renal clearance of approximately 158 mL/min, suggesting active



tubular secretion in addition to glomerular filtration. Approximately 97% of the avibactam dose is recovered in the urine, 95% within 12 h. Less than 1% of ceftazidime is excreted via the bile and less than 0.25% of avibactam is excreted into faeces.

#### Linearity/non-linearity

The pharmacokinetics of both ceftazidime and avibactam are approximately linear across the dose range studied (0.5 g to 2 g for ceftazidime and 0.05 g to 2 g for avibactam) for a single intravenous administration. No appreciable accumulation of ceftazidime or avibactam was observed following multiple intravenous infusions of 2 g/0.5 g of ceftazidime/avibactam administered every 8 hours for up to 11 days in healthy adults with normal renal function.

#### Special populations

##### *Renal impairment*

Elimination of ceftazidime and avibactam is decreased in patients with moderate or severe renal impairment. The average increases in avibactam AUC are 3.8-fold and 7-fold in subjects with moderate and severe renal impairment, see section 4.2.

##### *Hepatic impairment*

Mild to moderate hepatic impairment had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired. The pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established. The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied.

As ceftazidime and avibactam do not appear to undergo significant hepatic metabolism, the systemic clearance of either active substance is not expected to be significantly altered by hepatic impairment.

##### *Elderly patients ( $\geq 65$ years)*

Reduced clearance of ceftazidime was observed in elderly patients, which was primarily due to age-related decrease in renal clearance of ceftazidime. The mean elimination half-life of ceftazidime ranged from 3.5 to 4 hours following intravenous bolus dosing with 2 g every 12 hours in elderly patients aged 80 years or older.

Following a single intravenous administration of 500 mg avibactam as a 30-minute IV infusion, the elderly had a slower terminal half-life of avibactam, which may be attributed to age related decrease in renal clearance.

##### *Paediatric population*

The pharmacokinetics of ceftazidime and avibactam were evaluated in paediatric patients from 3 months to < 18 years of age with suspected or confirmed infections following a single dose of ceftazidime 50 mg/kg and avibactam 12.5 mg/kg for patients weighing < 40 kg or Zavicefta 2 g/0.5 g (ceftazidime 2 grams and avibactam 0.5 grams) for patients weighing  $\geq 40$  kg. Plasma concentrations of ceftazidime and avibactam were similar across all four age cohorts in the study (3 months to < 2 years, 2 to < 6 years, 6 to < 12 years, and 12 to < 18 years). Ceftazidime and avibactam  $AUC_{0-t}$  and  $C_{max}$  values in the two older cohorts (paediatric patients from 6 to < 18 years), which had more extensive pharmacokinetic sampling, were similar to those observed in healthy adult subjects with normal renal function that received Zavicefta 2 g/0.5 g. Data from this study and the two Phase 2 paediatric studies in patients with cIAI and cUTI were pooled with PK data from adults (Phase 1 to Phase 3) to update the population PK model, which was used to conduct simulations to assess PK/PD target attainment. Results from these simulations demonstrated that the recommended dose regimens for paediatric patients with cIAI, cUTI and HAP/VAP, including dose adjustments for patients with renal impairment, result in systemic exposure and PK/PD target attainment values that are similar to those in adults at the approved Zavicefta dose of 2 g/0.5 g administered over 2 hours, every 8 hours.

There is limited experience with the use of ceftazidime plus avibactam in the paediatric groups of 3 months to < 6 months. The recommended dosing regimens are based on simulations conducted using the final population PK models. Simulations demonstrated that the recommended dose regimens result in comparable exposures to other age groups with PK/PD target attainment > 90%. Based on data from the completed paediatric clinical trials, at the recommended dose regimens, there was no evidence of over or under exposure in the subjects aged 3 months to < 6 months.

In addition, there is very limited data in paediatric patients aged 3 months to < 2 years with impaired renal function ( $\text{CrCL} \leq 50 \text{ mL/min/1.73 m}^2$ ), with no data in severe renal impairment from the completed paediatric clinical trials. Population PK models for ceftazidime and avibactam were used to conduct simulations for patients with impaired renal function.

The pharmacokinetics of ceftazidime and avibactam were evaluated in 45 paediatric patients from birth to less than 3 months of age with suspected or confirmed infections following single and multiple doses of ceftazidime 20 mg/kg and avibactam 5 mg/kg for patients from birth to 28 days (including preterm neonates) or ceftazidime 30 mg/kg and avibactam 7.5 mg/kg for patients one month to less than 3 months. Plasma concentrations of ceftazidime and avibactam were similar across all age cohorts. Data from this study was used to update the previous population PK model and perform simulations to assess PK/PD target attainment. These simulations demonstrated that the recommended dose regimens for term neonates (gestational age [GA]  $\geq 37$  weeks), preterm neonates (GA 26 weeks to < 31 weeks and GA 31 to < 37 weeks) and infants aged 28 days to < 3 months, result in systemic exposure and PK/PD target attainment values that are similar to those in adults at the approved Zavicefta dose of 2 g/0.5 g administered over 2 hours, every 8 hours. There is no data in pre-term infants under 31 weeks GA from the completed paediatric clinical trials and dose recommendations in this age group are exclusively based on pharmacokinetic modelling.

#### *Gender and race*

The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race.

### **5.3 Preclinical safety data**

#### Ceftazidime

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproduction toxicity or genotoxicity. Carcinogenicity studies have not been conducted with ceftazidime.

#### Avibactam

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity. Carcinogenicity studies have not been conducted with avibactam.

#### Reproduction toxicity

In pregnant rabbits administered avibactam at 300 and 1000 mg/kg/day, there was a dose-related lower mean foetal weight and delayed ossification, potentially related to maternal toxicity. Plasma exposure levels at maternal and foetal NOAEL (100 mg/kg/day) indicate moderate to low margins of safety.

In the rat, no adverse effects were observed on embryofetal development or fertility. Following administration of avibactam throughout pregnancy and lactation in the rat, there was no effect on pup survival, growth or development, however there was an increase in incidence of dilation of the renal pelvis and ureters in less than 10% of the rat pups at maternal exposures greater than or equal to approximately 1.5 times human therapeutic exposures.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium carbonate (anhydrous)

### **6.2 Incompatibilities**

The compatibility of Zavicefta with other medicines has not been established. Zavicefta should not be mixed with or physically added to solutions containing other medicinal products.

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

### **6.3 Shelf life**

#### Dry powder

3 years.

#### After reconstitution

The reconstituted vial should be used immediately.

#### After dilution

##### *Infusion bags*

If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration 8 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 12 hours at 2 - 8°C, followed by up to 4 hours at not more than 25°C.

If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration > 8 mg/mL to 40 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 4 hours at not more than 25°C.

From a microbiological point of view, the medicinal product should be used immediately, unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed those stated above.

##### *Infusion syringes*

If the intravenous solution is prepared with diluents listed in section 6.6 (ceftazidime concentration  $\geq$  8 mg/mL to 40 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 6 hours at not more than 25°C.

From a microbiological point of view, the medicinal product should be used immediately unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed 6 hours at not more than 25°C.

### **6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

Store in the original package in order to protect from light.

For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.

### 6.5 Nature and contents of container

20 mL glass vial (Type 1) closed with a rubber (halobutyl) stopper and aluminium seal with flip-off cap.

The medicinal product is supplied in packs of 10 vials.

### 6.6 Special precautions for disposal and other handling

The powder must be reconstituted with water for injections and the resulting concentrate must then be immediately diluted prior to use. The reconstituted solution is a pale yellow solution and is free of particles.

Zavicefta (ceftazidime/avibactam) is a combination product; each vial contains 2 g of ceftazidime and 0.5 g of avibactam in a fixed 4:1 ratio. Dosage recommendations are based on the ceftazidime component only.

Standard aseptic techniques should be used for solution preparation and administration. Doses may be prepared in an appropriately sized infusion bag or infusion syringe.

Parenteral medicinal products should be inspected visually for particulate matter prior to administration.

Each vial is for single use only.

Any unused product or waste material should be disposed of in accordance with local requirements.

The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30 minutes.

#### Instructions for preparing adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE

NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 8-40 mg/mL of ceftazidime. All calculations should be completed prior to initiating these steps.

- **For paediatric patients 3 to 12 months of age**, detailed steps to prepare a 20 mg/mL concentration (sufficient for most scenarios) are provided below.
- **For paediatric patients from birth (including preterm) to < 3 months of age**, detailed steps to prepare a **10 mg/mL concentration** (sufficient for most scenarios) are provided below.

1. Prepare the **reconstituted solution (167.3 mg/mL)** of ceftazidime:
  - a) Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.
  - b) Withdraw the needle and shake the vial to give a clear solution.
  - c) Insert a gas relief needle through the vial closure **after** the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).
2. Prepare the **final solution** for infusion (final concentration must be **8-40 mg/mL** of ceftazidime):
  - a) Infusion bag: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution to an infusion bag containing any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, or Lactated Ringer's solution.
  - b) Infusion syringe: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to an infusion syringe.

Refer to Table 8 below.

Table 8: Preparation of Zavicefta for adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE.

Zavicefta dose (ceftazidime) <sup>1</sup>	Volume to withdraw from reconstituted vial	Final volume after dilution in infusion bag <sup>2</sup>	Final volume in infusion syringe <sup>3</sup>
2 g	Entire contents (approximately 12 mL)	50 mL to 250 mL	50 mL
1 g	6 mL	25 mL to 125 mL	25 mL to 50 mL
0.75 g	4.5 mL	19 mL to 93 mL	19 mL to 50 mL
All other doses	Volume (mL) calculated based on dose required:  <b>Dose (mg cefazidime) ÷ 167.3 mg/mL cefazidime</b>	Volume (mL) will vary based on infusion bag size availability and preferred final concentration (must be 8-40 mg/mL of cefazidime)	Volume (mL) will vary based on infusion syringe size availability and preferred final concentration (must be 8-40 mg/mL of cefazidime)

<sup>1</sup> Based on cefazidime component only.

<sup>2</sup> Dilute to final cefazidime concentration of 8 mg/mL for in-use stability up to 12 hours at 2 - 8°C, followed by up to 4 hours at not more than 25°C (i.e. dilute 2 g dose of cefazidime in 250 mL, 1 g dose of cefazidime in 125 mL, 0.75 g dose of cefazidime in 93 mL, etc.). All other cefazidime concentrations (> 8 mg/mL to 40 mg/mL) have in-use stability up to 4 hours at not more than 25°C.

<sup>3</sup> Dilute to final cefazidime concentration ≥ 8 mg/mL to 40 mg/mL for in-use stability up to 6 hours at not more than 25°C.

#### Paediatric patients 3 to 12 months of age

NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 20 mg/mL of cefazidime (sufficient for most scenarios). Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of cefazidime.

1. Prepare the **reconstituted solution (167.3 mg/mL of cefazidime)**:
  - a) Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.
  - b) Withdraw the needle and shake the vial to give a clear solution.
  - c) Insert a gas relief needle through the vial closure **after** the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).
2. Prepare the **final solution** for infusion to a final concentration of **20 mg/mL** of cefazidime:
  - a) Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to an infusion syringe.
  - b) Refer to Table 9, 10, or 11 below to confirm the calculations. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe. Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.

Table 9: Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with creatinine clearance (CrCL) > 50 mL/min/1.73 m<sup>2</sup>

Age and Zavicefta Dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of reconstituted solution to be withdrawn from vial (mL)	Volume of diluent to add for mixing (mL)
<b>6 months to 12 months</b>  <b>50 mg/kg of ceftazidime</b>	5	250	1.5	11
	6	300	1.8	13
	7	350	2.1	15
	8	400	2.4	18
	9	450	2.7	20
	10	500	3	22
	11	550	3.3	24
	12	600	3.6	27
<b>3 months to &lt; 6 months</b>  <b>40 mg/kg of ceftazidime</b>	4	160	1	7.4
	5	200	1.2	8.8
	6	240	1.4	10
	7	280	1.7	13
	8	320	1.9	14
	9	360	2.2	16
	10	400	2.4	18

<sup>1</sup> Based on ceftazidime component only.

Table 10: Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 31 to 50 mL/min/1.73 m<sup>2</sup>

Age and Zavicefta Dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of reconstituted solution to be withdrawn from vial (mL)	Volume of diluent to add for mixing (mL)
<b>6 months to 12 months</b>  <b>25 mg/kg of ceftazidime</b>	5	125	0.75	5.5
	6	150	0.9	6.6
	7	175	1	7.4
	8	200	1.2	8.8
	9	225	1.3	9.6
	10	250	1.5	11
	11	275	1.6	12
	12	300	1.8	13
<b>3 months to &lt; 6 months</b>  <b>20 mg/kg of ceftazidime</b>	4	80	0.48	3.5
	5	100	0.6	4.4
	6	120	0.72	5.3
	7	140	0.84	6.2
	8	160	1	7.4
	9	180	1.1	8.1
	10	200	1.2	8.8

<sup>1</sup> Based on ceftazidime component only.

Table 11: Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 16 to 30 mL/min/1.73 m<sup>2</sup>

Age and Zavicefta Dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of reconstituted solution to be withdrawn from vial (mL)	Volume of diluent to add for mixing (mL)
<b>6 months to 12 months</b>  <b>18.75 mg/kg of ceftazidime</b>	5	93.75	0.56	4.1
	6	112.5	0.67	4.9
	7	131.25	0.78	5.7
	8	150	0.9	6.6
	9	168.75	1	7.4
	10	187.5	1.1	8.1
	11	206.25	1.2	8.8
<b>3 months to &lt; 6 months</b>  <b>15 mg/kg of ceftazidime</b>	4	60	0.36	2.7
	5	75	0.45	3.3
	6	90	0.54	4
	7	105	0.63	4.6
	8	120	0.72	5.3
	9	135	0.81	6
	10	150	0.9	6.6

<sup>1</sup> Based on ceftazidime component only.

Paediatric patients from birth (including preterm) to < 3 months of age:

NOTE: The following procedure describes the steps to prepare a stock infusion solution with a final concentration of 10 mg/mL of ceftazidime appropriate for administering doses under 250 mg to paediatric patients from birth (including preterm) to < 3 months of age. Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.

1. Prepare the **reconstituted solution (167.3 mg/mL)** of ceftazidime:
  - a) Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.
  - b) Withdraw the needle and shake the vial to give a clear solution.
  - c) Insert a gas relief needle through the vial closure **after** the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).
2. Prepare the **final stock solution** for infusion to a final concentration of **10 mg/mL** of ceftazidime:
  - a) Further dilute the reconstituted solution by transferring 3 mL of the reconstituted solution to an infusion bag or a syringe containing 47 mL of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to provide a final volume of 50 mL.
  - b) Mix thoroughly (e.g. gently invert the infusion bag or using a syringe connector gently pass the solution back and forth at least 5 times between 2 syringes).
  - c) Transfer an appropriate volume of the **10 mg/mL** of ceftazidime stock solution to an infusion syringe. Refer to Table 12 below for the volume of the stock solution to transfer to the infusion syringe to be administered. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe.  
Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.

Table 12: Zavicefta dosing in paediatric patients from birth (including preterm) to < 3 months of age using a 50 mL stock solution of Zavicefta (final concentration of 10 mg/mL of ceftazidime) prepared with 3 mL reconstituted solution withdrawn from the vial and added to 47 mL diluent.

Age and Zavicefta dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of 10 mg/mL (ceftazidime) stock solution to be administered (mL)
Full term infants (gestation ≥ 37 weeks) from > 28 days to < 3 months  OR  Preterm infants from > 44 weeks to < 53 weeks PMA  <b>30 mg/kg of ceftazidime</b>	3	90	9
	3.5	105	10.5
	4	120	12
	4.5	135	13.5
	5	150	15
	5.5	165	16.5
	6	180	18
	6.5	195	19.5
	7	210	21
	7.5	225	22.5
Full term neonates (gestation ≥ 37 weeks) from birth to ≤ 28 days  OR  Preterm neonates and infants from 26 to ≤ 44 weeks PMA  <b>20 mg/kg of ceftazidime</b>	0.8	16	1.6
	1	20	2
	1.2	24	2.4
	1.4	28	2.8
	1.6	32	3.2
	1.8	36	3.6
	2	40	4
	2.2	44	4.4
	2.4	48	4.8
	2.6	52	5.2
	2.8	56	5.6
	3	60	6
	3.5	70	7
	4	80	8
	4.5	90	9
	5	100	10
5.5	110	11	
6	120	12	

<sup>1</sup> Based on ceftazidime component only.

## 7. MARKETING AUTHORISATION HOLDER

Pfizer Ireland Pharmaceuticals Unlimited Company  
Operations Support Group  
Ringaskiddy, County Cork  
Ireland

## 8. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1109/001



**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 24 June 2016

Date of latest renewal: 11 February 2021

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

**ANNEX II**

- A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING  
AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND  
EFFECTIVE USE OF THE MEDICINAL PRODUCT**

## **A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer(s) responsible for batch release

ACS Dobfar S.p.A  
VIA A. FLEMING, 2  
VERONA 37135  
ITALY

## **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of European Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## **D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON**

**1. NAME OF THE MEDICINAL PRODUCT**

ZAVICEFTA 2 g/0.5g powder for concentrate for solution for infusion  
ceftazidime/avibactam

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam.

**3. LIST OF EXCIPIENTS**

This product has high sodium content (see package leaflet for further details).

**4. PHARMACEUTICAL FORM AND CONTENTS**

powder for concentrate for solution for infusion  
10 vials

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intravenous use  
Dilute before use

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Pfizer Ireland Pharmaceuticals Unlimited Company  
Operations Support Group  
Ringaskiddy, County Cork  
Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1109/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**VIAL LABEL**

**1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

ZAVICEFTA 2 g/0.5 g powder for concentrate  
ceftazidime/avibactam  
IV

**2. METHOD OF ADMINISTRATION**

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

ceftazidime 2 g/avibactam 0.5 g

**6. OTHER**



**B. PACKAGE LEAFLET**

## Package leaflet: Information for the user

### Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion ceftazidime/avibactam

**Read all of this leaflet carefully before you start using this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### **What is in this leaflet:**

1. What Zavicefta is and what it is used for
2. What you need to know before you use Zavicefta
3. How to use Zavicefta
4. Possible side effects
5. How to store Zavicefta
6. Contents of the pack and other information

#### **1. What Zavicefta is and what it is used for**

##### **What Zavicefta is**

Zavicefta is an antibiotic medicine that contains two active substances ceftazidime and avibactam.

- Ceftazidime belongs to the group of antibiotics called “cephalosporins”. It can kill many types of bacteria.
- Avibactam is a “beta-lactamase inhibitor” that helps ceftazidime kill some bacteria that it cannot kill on its own.

##### **What Zavicefta is used for**

Zavicefta is used in adults and paediatric patients from birth to treat:

- infections of the stomach and gut (abdomen)
- infections of the bladder or kidneys called “urinary tract infections”
- an infection of the lungs called “pneumonia”
- infections caused by bacteria that other antibiotics may not be able to kill

Zavicefta is used in adults to treat infection of the blood associated with infections of the abdomen, urinary tract, or pneumonia.

##### **How Zavicefta works**

Zavicefta works by killing certain types of bacteria, which can cause serious infections.

#### **2. What you need to know before you use Zavicefta**

##### **Do not use Zavicefta if:**

- you are allergic to ceftazidime, avibactam or any of the other ingredients of this medicine (listed in section 6)
- you are allergic to other cephalosporin antibiotics
- you have ever had a severe allergic reaction to other antibiotics belonging to the penicillin or carbapenem groups

Do not use Zavicefta if any of the above apply to you. If you are not sure, talk to your doctor or nurse before using Zavicefta.

## **Warnings and precautions**

Talk to your doctor or nurse before using Zavicefta if:

- you have ever had any allergic reaction (even if only a skin rash) to other antibiotics belonging to the penicillin or carbapenem groups.
- serious skin reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP) have been reported in association with ceftazidime treatment. Seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.
- you have kidney problems - your doctor may give you a lower dose to make sure you don't get too much medicine. This could cause symptoms such as fits (see section **If you use more Zavicefta than you should**).

If any of the above apply to you (or you are not sure), talk to your doctor or nurse before using Zavicefta.

Talk to your doctor or nurse if you suffer from diarrhoea during your treatment.

### Other infections

There is a small possibility that you may get a different infection caused by another bacteria during or after treatment with Zavicefta. These include thrush (fungal infections of the mouth or genital area).

### Lab tests

Tell your doctor that you are taking Zavicefta if you are going to have any tests. This is because you may get an abnormal result with a test called "DAGT" or "Coombs". This test looks for antibodies that fight against your red blood cells.

Zavicefta can also affect the results of some urine tests for sugar. Tell the person taking the sample that you have been given Zavicefta.

### **Other medicines and Zavicefta**

Tell your doctor or nurse if you are using, have recently used or might use any other medicines.

Talk to your doctor before using Zavicefta if you are taking any of the following medicines:

- an antibiotic called chloramphenicol
- a type of antibiotic called an aminoglycoside – such as gentamicin, tobramycin
- a water tablet called furosemide
- a medicine for gout called probenecid

Tell your doctor before using Zavicefta if any of the above apply to you.

### **Pregnancy and breast-feeding**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.

### **Driving and using machines**

Zavicefta may make you feel dizzy. This may affect you being able to drive, use tools or machines.

### **Zavicefta contains sodium**

This medicine contains approximately 146 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 7.3% of the recommended maximum daily dietary intake for sodium for an adult.

Talk to your doctor or pharmacist if you need 3 or more vials daily for a prolonged period, especially if you have been advised to have a low salt (sodium) diet.

### **3. How to use Zavicefta**

Zavicefta will be given to you by a doctor or a nurse.

#### **How much to use**

The recommended dose for adults is one vial (2 g of ceftazidime and 0.5 g of avibactam), every 8 hours. The dose for paediatric patients from birth will be calculated by the doctor based on the weight and age of the child.

It is given as a drip into a vein – this will normally take about 2 hours.

A course of treatment usually lasts from 5 to up to 14 days, depending on the type of infection you have and how you respond to treatment.

#### People with kidney problems

If you have kidney problems your doctor may lower your dose. This is because Zavicefta is removed from your body by the kidneys.

#### **If you use more Zavicefta than you should**

Zavicefta will be given to you by a doctor or a nurse, so it is unlikely you will be given the wrong dose. However, if you have side effects or think you have been given too much Zavicefta, tell your doctor or nurse straight away. If you have too much Zavicefta it could have an effect on the brain and cause fits or coma.

#### **If you miss a dose of Zavicefta**

If you think you have missed a dose, tell your doctor or nurse straight away.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

### **4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:

#### **Serious side effects**

Tell your doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:

- reddish patches on the trunk, the patches are target-like macules or circular, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
- widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).
- a red, scaly widespread rash with bumps under the skin and blisters accompanied by fever. The symptoms usually appear at the initiation of treatment (acute generalised exanthematous pustulosis).
- severe allergic reactions – signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing, or sudden chest pain (which may be a sign of Kounis syndrome). These reactions may be life-threatening.
- diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus – this may happen during or after treatment is stopped with Zavicefta. If this happens do not take medicines that stop or slow bowel movement.

Tell your doctor straight away if you notice any of the serious side effects above.

### Other side effects

Tell your doctor or nurse if you notice any of the following side effects:

#### Very common: (may affect more than 1 in 10 people)

- abnormal result with a test called “DAGT” or “Coombs”. This test looks for antibodies that fight against your red blood cells. It is possible that this could cause anaemia (which may make you feel tired) and jaundice (yellowing of the skin and eyes)

#### Common: (may affect up to 1 in 10 people)

- fungal infections, including those of the mouth and vagina
- change in the number of some types of blood cells (called “eosinophils” and “thrombocytes”) – shown in blood tests
- headache
- feeling dizzy
- feeling sick (nausea) or being sick (vomiting)
- stomach pain
- diarrhoea
- increase in the amount of some enzymes produced by your liver - shown in blood tests
- raised itchy skin rash (“hives”)
- itchiness
- redness, pain or swelling where Zavicefta was given into a vein
- fever

#### Uncommon: (may affect up to 1 in 100 people)

- increase in the number of a type of blood cell (called “lymphocytes”) – shown in blood tests
- decrease in the number of some types of blood cells (called “leucocytes”) - shown in blood tests
- tingling or numbness
- bad taste in your mouth
- an increase in the level of some types of substances in your blood (called “creatinine” and “urea”). These show how well your kidneys are working.

#### Very rare: (may affect up to 1 in 10,000 people)

- swelling in a part of the kidney that causes a reduction in its normal working function

#### Not known: (frequency cannot be estimated from the available data)

- significant decrease in the type of white blood cells used to fight infection - shown in blood tests
- decrease in the number of red blood cells (haemolytic anaemia) – shown in blood tests
- severe allergic reaction (see **Serious side effects**, above)
- yellowing of the whites of the eyes or skin
- sudden onset of a severe rash or blistering or peeling skin, possibly accompanied by a high fever or joint pain (these may be signs of more serious medical conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, a condition known as DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms or acute generalised exanthematous pustulosis (AGEP))
- swelling under the skin, particularly lips and around the eyes

Tell your doctor or nurse if you notice any of the side effects listed above.

### Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

## 5. How to store Zavicefta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month.

Store in the original package in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer require. These measures will help to protect the environment.

## 6. Contents of the pack and other information

### What Zavicefta contains

- The active substances are ceftazidime and avibactam. Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam.
- The other ingredient is sodium carbonate (anhydrous) (see section 2 “Zavicefta contains sodium”).

### What Zavicefta looks like and contents of the pack

Zavicefta is a white to yellow powder for concentrate for solution for infusion in a vial. It is available in packs containing 10 vials.

### Marketing Authorisation Holder

Pfizer Ireland Pharmaceuticals Unlimited Company  
Operations Support Group  
Ringaskiddy, County Cork  
Ireland

### Manufacturer

ACS Dobfar S.p.A.  
Via Alessandro Fleming 2  
Verona 37135  
Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**  
**Luxembourg/Luxemburg**  
Pfizer NV/SA  
Tél/Tel: +32 (0)2 554 62 11

**Lietuva**  
Pfizer Luxembourg SARL filialas Lietuvoje  
Tel: +370 5 251 4000

**България**  
Пфайзер Люксембург САРЛ, Клон България  
Тел.: +359 2 970 4333

**Magyarország**  
Pfizer Kft.  
Tel.: + 36 1 488 37 00

**Česká republika**  
Pfizer, spol. s r.o.  
Tel: +420 283 004 111

**Malta**  
Vivian Corporation Ltd.  
Tel: +356 21344610

**Danmark**  
Pfizer ApS  
Tlf.: +45 44 20 11 00

**Nederland**  
Pfizer bv  
Tel: +31 (0)800 63 34 636

**Deutschland**

Pfizer PHARMA GmbH  
Tel: +49 (0)30 550055-51000

**Eesti**

Pfizer Luxembourg SARL Eesti filiaal  
Tel: +372 666 7500

**Ελλάδα**

Pfizer Ελλάς A.E.  
Τηλ: +30 210 6785800

**España**

Pfizer, S.L.  
Tel: +34 91 490 99 00

**France**

Pfizer  
Tél: +33 (0)1 58 07 34 40

**Hrvatska**

Pfizer Croatia d.o.o.  
Tel: +385 1 3908 777

**Ireland**

Pfizer Healthcare Ireland Unlimited Company  
Tel: +1800 633 363 (toll free)  
Tel: +44 (0)1304 616161

**Ísland**

Icepharma hf.  
Sími: +354 540 8000

**Italia**

Pfizer S.r.l.  
Tel: +39 06 33 18 21

**Κύπρος**

Pfizer Ελλάς A.E. (Cyprus Branch)  
Τηλ: +357 22817690

**Latvija**

Pfizer Luxembourg SARL filiāle Latvijā  
Tel: + 371 670 35 775

**Norge**

Pfizer AS  
Tlf: +47 67 52 61 00

**Österreich**

Pfizer Corporation Austria Ges.m.b.H.  
Tel: +43 (0)1 521 15-0

**Polska**

Pfizer Polska Sp. z o.o.  
Tel.: +48 22 335 61 00

**Portugal**

Laboratórios Pfizer, Lda.  
Tel: +351 21 423 5500

**România**

Pfizer Romania S.R.L.  
Tel: +40 (0) 21 207 28 00

**Slovenija**

Pfizer Luxembourg SARL  
Pfizer, podružnica za svetovanje s področja  
farmacevtske dejavnosti, Ljubljana  
Tel: +386 (0)1 52 11 400

**Slovenská republika**

Pfizer Luxembourg SARL, organizačná zložka  
Tel: + 421 2 3355 5500

**Suomi/Finland**

Pfizer Oy  
Puh/Tel: +358 (0)9 430 040

**Sverige**

Pfizer AB  
Tel: +46 (0)8 550 520 00

**This leaflet was last revised in MM/YYYY**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<https://www.ema.europa.eu>.

---

**The following information is intended for healthcare professionals only:**

Important: Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

The compatibility of Zavicefta with other medicines has not been established. Zavicefta should not be mixed with or physically added to solutions containing other medicinal products.

The powder must be reconstituted with water for injections and the resulting concentrate must then be immediately diluted prior to use. The reconstituted solution is a pale yellow solution and is free of particles.

Mix gently to reconstitute and check to see that the contents have dissolved completely. Parenteral medicinal products should be inspected visually for particulate matter prior to administration.

*Infusion bags*

If the intravenous solution is prepared with diluents listed in section 6.6 of the SmPC (ceftazidime concentration 8 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 12 hours at 2 - 8°C, followed by up to 4 hours at not more than 25°C.

If the intravenous solution is prepared with diluents listed in section 6.6 of the SmPC (ceftazidime concentration > 8 mg/mL to 40 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 4 hours at not more than 25°C.

From a microbiological point of view, the medicinal product should be used immediately, unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed those stated above.

*Infusion syringes*

If the intravenous solution is prepared with diluents listed in section 6.6 of the SmPC (ceftazidime concentration  $\geq$  8 mg/mL to 40 mg/mL), the chemical and physical in-use stability has been demonstrated (from initial vial puncture) for up to 6 hours at not more than 25°C.

From a microbiological point of view, the medicinal product should be used immediately unless reconstitution and dilution have taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not exceed 6 hours at not more than 25°C.

Zavicefta (ceftazidime/avibactam) is a combination product; each vial contains 2 g of ceftazidime and 0.5 g of avibactam in a fixed 4:1 ratio. Dosage recommendations are based on the ceftazidime component only.

Standard aseptic techniques should be used for solution preparation and administration. Doses may be prepared in an appropriately sized infusion bag or infusion syringe.

The resulting solution should be administered over 120 minutes.

Each vial is for single use only.

Any unused product or waste material should be disposed of in accordance with local requirements.

The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30 minutes.



Instructions for preparing adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE:

NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 8-40 mg/mL of ceftazidime. All calculations should be completed prior to initiating these steps.

- **For paediatric patients 3 to 12 months of age**, detailed steps to prepare a 20 mg/mL concentration (sufficient for most scenarios) are provided below.
  - **For paediatric patients from birth (including preterm) to < 3 months of age**, detailed steps to prepare a **10 mg/mL concentration** (sufficient for most scenarios) are provided below.
1. Prepare the **reconstituted solution (167.3 mg/mL of ceftazidime)**:
    - a) Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.
    - b) Withdraw the needle and shake the vial to give a clear solution.
    - c) Insert a gas relief needle through the vial closure **after** the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).
  2. Prepare the **final solution** for infusion (final concentration must be **8-40 mg/mL** of ceftazidime):
    - a) Infusion bag: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution to an infusion bag containing any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, or Lactated Ringer's solution.
    - b) Infusion syringe: Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to an infusion syringe.

Refer to the Table below.

Preparation of Zavicefta for adult and paediatric doses in INFUSION BAG or in INFUSION SYRINGE.

Zavicefta Dose (ceftazidime) <sup>1</sup>	Volume to withdraw from reconstituted vial	Final volume after dilution in infusion bag <sup>2</sup>	Final volume in infusion syringe <sup>3</sup>
2 g	Entire contents (approximately 12 mL)	50 mL to 250 mL	50 mL
1 g	6 mL	25 mL to 125 mL	25 mL to 50 mL
0.75 g	4.5 mL	19 mL to 93 mL	19 mL to 50 mL
All other doses	Volume (mL) calculated based on dose required:  <b>Dose (mg ceftazidime) ÷ 167.3 mg/mL ceftazidime</b>	Volume (mL) will vary based on infusion bag size availability and preferred final concentration (must be 8-40 mg/mL of ceftazidime)	Volume (mL) will vary based on infusion syringe size availability and preferred final concentration (must be 8-40 mg/mL of ceftazidime)

<sup>1</sup> Based on ceftazidime component only.

<sup>2</sup> Dilute to final ceftazidime concentration of 8 mg/mL for in-use stability up to 12 hours at 2 - 8°C, followed by up to 4 hours at not more than 25°C (i.e. dilute 2 g dose of ceftazidime in 250 mL, 1 g dose of ceftazidime in 125 mL, 0.75 g dose of ceftazidime in 93 mL, etc.). All other ceftazidime concentrations (> 8 mg/mL to 40 mg/mL) have in-use stability up to 4 hours at not more than 25°C.

<sup>3</sup> Dilute to final ceftazidime concentration ≥ 8 mg/mL to 40 mg/mL for in-use stability up to 6 hours at not more than 25°C.

### Paediatric patients 3 to 12 months of age

NOTE: The following procedure describes the steps to prepare an infusion solution with a final concentration of 20 mg/mL of ceftazidime (sufficient for most scenarios). Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.

1. Prepare the **reconstituted solution (167.3 mg/mL** of ceftazidime):
  - a) Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.
  - b) Withdraw the needle and shake the vial to give a clear solution.
  - c) Insert a gas relief needle through the vial closure **after** the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).
2. Prepare the **final solution** for infusion to a final concentration of **20 mg/mL** of ceftazidime:
  - a) Further dilute the reconstituted solution by transferring an appropriately calculated volume of the reconstituted solution combined with a sufficient volume of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to an infusion syringe.
  - b) Refer to the Tables below to confirm the calculations. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe. Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.

Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with creatinine clearance (CrCL) > 50 mL/min/1.73 m<sup>2</sup>

Age and Zavicefta Dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of reconstituted solution to be withdrawn from vial (mL)	Volume of diluent to add for mixing (mL)
<b>6 months to 12 months</b>  <b>50 mg/kg of ceftazidime</b>	5	250	1.5	11
	6	300	1.8	13
	7	350	2.1	15
	8	400	2.4	18
	9	450	2.7	20
	10	500	3	22
	11	550	3.3	24
	12	600	3.6	27
<b>3 months to &lt; 6 months</b>  <b>40 mg/kg of ceftazidime</b>	4	160	1	7.4
	5	200	1.2	8.8
	6	240	1.4	10
	7	280	1.7	13
	8	320	1.9	14
	9	360	2.2	16
	10	400	2.4	18

<sup>1</sup> Based on ceftazidime component only.

Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 31 to 50 mL/min/1.73 m<sup>2</sup>

Age and Zavicefta dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of reconstituted solution to be withdrawn from vial (mL)	Volume of diluent to add for mixing (mL)
<b>6 months to 12 months</b>  <b>25 mg/kg of ceftazidime</b>	5	125	0.75	5.5
	6	150	0.9	6.6
	7	175	1	7.4
	8	200	1.2	8.8
	9	225	1.3	9.6
	10	250	1.5	11
	11	275	1.6	12
	12	300	1.8	13
<b>3 months to &lt; 6 months</b>  <b>20 mg/kg of ceftazidime</b>	4	80	0.48	3.5
	5	100	0.6	4.4
	6	120	0.72	5.3
	7	140	0.84	6.2
	8	160	1	7.4
	9	180	1.1	8.1
	10	200	1.2	8.8

<sup>1</sup> Based on ceftazidime component only.

Preparation of Zavicefta (final concentration of 20 mg/mL of ceftazidime) in paediatric patients 3 to 12 months of age with CrCL 16 to 30 mL/min/1.73 m<sup>2</sup>

Age and Zavicefta dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of reconstituted solution to be withdrawn from vial (mL)	Volume of diluent to add for mixing (mL)
<b>6 months to 12 months</b>  <b>18.75 mg/kg of ceftazidime</b>	5	93.75	0.56	4.1
	6	112.5	0.67	4.9
	7	131.25	0.78	5.7
	8	150	0.9	6.6
	9	168.75	1	7.4
	10	187.5	1.1	8.1
	11	206.25	1.2	8.8
	12	225	1.3	9.6
<b>3 months to &lt; 6 months</b>  <b>15 mg/kg of ceftazidime</b>	4	60	0.36	2.7
	5	75	0.45	3.3
	6	90	0.54	4
	7	105	0.63	4.6
	8	120	0.72	5.3
	9	135	0.81	6
	10	150	0.9	6.6

<sup>1</sup> Based on ceftazidime component only.

Paediatric patients from birth (including preterm) to < 3 months of age:

NOTE: The following procedure describes the steps to prepare a stock infusion solution with a final concentration of 10 mg/mL of ceftazidime appropriate for administering doses under 250 mg to paediatric patients from birth (including preterm) to < 3 months of age. Alternative concentrations may be prepared, but must have a final concentration range of 8-40 mg/mL of ceftazidime.

1. Prepare the **reconstituted solution (167.3 mg/mL of ceftazidime)**:
  - a) Insert the syringe needle through the vial closure and inject 10 mL of sterile water for injections.
  - b) Withdraw the needle and shake the vial to give a clear solution.
  - c) Insert a gas relief needle through the vial closure **after** the product has dissolved to relieve the internal pressure (this is important to preserve product sterility).
2. Prepare the **final stock solution** for infusion to a final concentration of **10 mg/mL** of ceftazidime:
  - a) Further dilute the reconstituted solution by transferring 3 mL of the reconstituted solution to an infusion bag or a syringe containing 47 mL of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection) to provide a final volume of 50 mL.
  - b) Mix thoroughly (e.g. gently invert the infusion bag or using a syringe connector gently pass the solution back and forth at least 5 times between 2 syringes).
  - c) Transfer an appropriate volume of the **10 mg/mL** of ceftazidime stock solution to an infusion syringe. Refer to the table below for the volume of the stock solution to transfer to the infusion syringe to be administered. Values shown are approximate as it may be necessary to round to the nearest graduation mark of an appropriately sized syringe.  
Note that the tables are NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.

Zavicefta dosing in paediatric patients from birth (including preterm) to < 3 months of age using a 50 mL stock solution of Zavicefta (final concentration of 10 mg/mL of ceftazidime) prepared with 3 mL reconstituted solution withdrawn from the vial and added to 47 mL diluent.

Age and Zavicefta dose (mg/kg) <sup>1</sup>	Weight (kg)	Dose (mg ceftazidime)	Volume of 10 mg/mL (ceftazidime) stock solution to be administered (mL)
Full term infants (gestation ≥ 37 weeks) from > 28 days to < 3 months  OR  Preterm infants from > 44 weeks to < 53 weeks PMA  <b>30 mg/kg of ceftazidime</b>	3	90	9
	3.5	105	10.5
	4	120	12
	4.5	135	13.5
	5	150	15
	5.5	165	16.5
	6	180	18
	6.5	195	19.5
	7	210	21
	7.5	225	22.5
Full term neonates (gestation ≥ 37 weeks) from birth to ≤ 28 days  OR  Preterm neonates and infants from 26 to ≤ 44 weeks PMA  <b>20 mg/kg of ceftazidime</b>	0.8	16	1.6
	1	20	2
	1.2	24	2.4
	1.4	28	2.8
	1.6	32	3.2
	1.8	36	3.6
	2	40	4
	2.2	44	4.4
	2.4	48	4.8
	2.6	52	5.2
	2.8	56	5.6
	3	60	6
	3.5	70	7

	4	80	8
	4.5	90	9
	5	100	10
	5.5	110	11
	6	120	12

<sup>1</sup> Based on ceftazidime component only.